Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1...
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
About this item
Full title
Author / Creator
Falchook, Gerald S, Dr , Long, Georgina V, PhD , Kurzrock, Razelle, Prof , Kim, Kevin B, MD , Arkenau, Tobias H, PhD , Brown, Michael P, PhD , Hamid, Omid, MD , Infante, Jeffrey R, MD , Millward, Michael, MD , Pavlick, Anna C, MD , O’Day, Steven J, MD , Blackman, Samuel C, PhD , Curtis, C Martin, BA , Lebowitz, Peter, PhD , Ma, Bo, PhD , Ouellet, Daniele, PhD and Kefford, Richard F, Prof
Publisher
Kidlington: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in patients with incurable solid tumours, especially those with melanoma and untreated, asymptomatic brain metastases. Methods We undertook a phase 1 trial between...
Alternative Titles
Full title
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Authors, Artists and Contributors
Author / Creator
Long, Georgina V, PhD
Kurzrock, Razelle, Prof
Kim, Kevin B, MD
Arkenau, Tobias H, PhD
Brown, Michael P, PhD
Hamid, Omid, MD
Infante, Jeffrey R, MD
Millward, Michael, MD
Pavlick, Anna C, MD
O’Day, Steven J, MD
Blackman, Samuel C, PhD
Curtis, C Martin, BA
Lebowitz, Peter, PhD
Ma, Bo, PhD
Ouellet, Daniele, PhD
Kefford, Richard F, Prof
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1399903452
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1399903452
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(12)60398-5
